PET-Imaging and longitudinal cohorts
PET-Imaging is an integrated part of the longitudinal cohort studies which aim to assess factors associated with brain-pathology and factors which are associated with cognitive performance and healthy aging.
Cerebral beta-amyloid load is detected Flutemetamol in an ongoing cohort of subjects, who are healthy or show mild cognitive impairment (Identification of Factors associated with healthy aging and cognitive decline-ID-cog“). Furthermore we study subjects above the age of 85 years within the project “Cognitive Status, Quality of Life, Brain Structure and Beta-Amyloid Deposition” in the Oldest Old. Additional Tau-PET will start in 2016 to complement these data sets. Through the collaborative aspects of these studies with the other research groups in the department we are able to study how presence or absence of brain pathology is associated with cognition; structural and physiological MR-measurements; biological factors with a focus on immunological, genetic and metabolic aspects as well as with clinical and lifestyle factors. With this approach we hope, that we can identify on the one hand factors which are preventive on the formation of pathology and on the other hand factors which relate to cognitive stability in the presence of significant brain pathology. This knowledge could give rise to new diagnostic and therapeutic strategies. Another focus of our research is to assess the clinical value of amyloid-imaging. Here we conduct a clinical trial which aims to assess the influence of a Flutemetamol-Scan on clinical decisions and outcome in various conditions where amyloid-PET can be considered useful. (ClinicalTrials.gov Identifier: NCT02353949)